Yuan N, Kaul M
J Neuroimmune Pharmacol. 2019; 16(1):90-112.
PMID: 31385157
PMC: 7233291.
DOI: 10.1007/s11481-019-09868-9.
Storelli F, Samer C, Reny J, Desmeules J, Daali Y
Clin Pharmacokinet. 2018; 57(10):1267-1293.
PMID: 29667038
DOI: 10.1007/s40262-018-0650-9.
Damronglerd P, Sukasem C, Thipmontree W, Puangpetch A, Kiertiburanakul S
Pharmgenomics Pers Med. 2015; 8:155-62.
PMID: 26622191
PMC: 4638311.
DOI: 10.2147/PGPM.S86446.
Mollan K, Smurzynski M, Eron J, Daar E, Campbell T, Sax P
Ann Intern Med. 2014; 161(1):1-10.
PMID: 24979445
PMC: 4204642.
DOI: 10.7326/M14-0293.
Yuce-Artun N, Kose G, Suzen H
Mol Biol Rep. 2014; 41(6):3891-6.
PMID: 24562623
DOI: 10.1007/s11033-014-3256-9.
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.
Naidoo P, Chetty V, Chetty M
Eur J Clin Pharmacol. 2014; 70(4):379-89.
PMID: 24390631
DOI: 10.1007/s00228-013-1634-1.
Neurological and psychiatric adverse effects of antiretroviral drugs.
Abers M, Shandera W, Kass J
CNS Drugs. 2013; 28(2):131-45.
PMID: 24362768
DOI: 10.1007/s40263-013-0132-4.
Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory.
Varshney E, Saha N, Tandon M, Shrivastava V, Ali S
Springerplus. 2013; 1:34.
PMID: 23961363
PMC: 3725906.
DOI: 10.1186/2193-1801-1-34.
Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.
Li J, Menard V, Benish R, Jurevic R, Guillemette C, Stoneking M
Pharmacogenomics. 2012; 13(5):555-70.
PMID: 22462748
PMC: 3390746.
DOI: 10.2217/pgs.11.160.
Neuropsychiatric sequelae in an efavirenz treated patient with hepatitis B.
Salter E, Patel A
BMJ Case Rep. 2011; 2009.
PMID: 22121393
PMC: 3029553.
DOI: 10.1136/bcr.07.2009.2061.
Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.
Sanchez A, Cabrera S, Santos D, Valverde M, Fuertes A, Dominguez-Gil A
Antimicrob Agents Chemother. 2011; 55(11):5314-24.
PMID: 21896912
PMC: 3195031.
DOI: 10.1128/AAC.00194-11.
Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.
Figueroa S, Gomez A, Martin A, Valverde Merino M, Hurle A, Sanchez M
Clin Drug Investig. 2010; 30(6):405-11.
PMID: 20441246
DOI: 10.1007/BF03256910.
Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?.
Rotger M, Telenti A
Eur J Clin Pharmacol. 2008; 64(4):335-6.
PMID: 18188549
DOI: 10.1007/s00228-007-0440-z.
Adherence-resistance relationships to combination HIV antiretroviral therapy.
Bangsberg D, Kroetz D, Deeks S
Curr HIV/AIDS Rep. 2007; 4(2):65-72.
PMID: 17547827
DOI: 10.1007/s11904-007-0010-0.
CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.
Mehlotra R, Bockarie M, Zimmerman P
Br J Clin Pharmacol. 2007; 64(3):391-5.
PMID: 17391322
PMC: 2000644.
DOI: 10.1111/j.1365-2125.2007.02884.x.
Neuropsychiatric complications of antiretroviral therapy.
Cespedes M, Aberg J
Drug Saf. 2006; 29(10):865-74.
PMID: 16970510
DOI: 10.2165/00002018-200629100-00004.
Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea.
Mehlotra R, Ziats M, Bockarie M, Zimmerman P
Eur J Clin Pharmacol. 2006; 62(4):267-75.
PMID: 16506047
PMC: 4450653.
DOI: 10.1007/s00228-005-0092-9.
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Back D, Owen A, Khoo S
Clin Pharmacokinet. 2006; 45(2):213-4.
PMID: 16485918
DOI: 10.2165/00003088-200645020-00006.